Boston Therapeutics has completed a trial evaluating the Sugardown dietary supplement at the University of Sydney.
Sugardown helps reduce post-meal elevation of blood glucose.
In the trial, Sugardown was evaluated in overweight healthy adults with a mean body mass index (BMI) value of 27.3kg/m².
Boston president Ken Tassey said the study has important endpoints that support the expectation that Sugardown can be a powerful tool for many people who struggle with blood sugar management.
Boston chief technology officer Joan Sellers said they were in the process of summarising the data to demonstrate the significant reduction in postprandial blood glucose after consumption of Sugardown chewable tablets.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData